Summit Therapeutics PLC (LON:SUMM)

Summit Therapeutics PLC (LON:SUMM)


Share Price
31.00 p
Change
0 (0.00 %)
Market Cap
£49.72 m
Proactive Investors - Run By Investors For Investors

Summit Therapeutics PLC

Summit Therapeutics is a leader in antibiotic innovation. Summit’s new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. The company is currently developing new mechanism antibiotics for infections caused by C. difficile, N. Gonorrhoeae and ESKAPE pathogens and is using its proprietary...

EPIC: SUMM
Market: AIM:SUMM
52-week High/Low: 209.00p / 9.50p
Sector: Pharma & Biotech
Market Cap: £49.72 m
Website: www.summitplc.com
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of Summit Therapeutics PLC


Summit Therapeutics PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use